Journal of the American Society of Hypertension
Volume 1, Issue 2 , Pages 99-103 , March 2007

Renalase is a novel renal hormone that regulates cardiovascular function

  • Gary V. Desir, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Gary V. Desir, MD, Section of Nephrology, Department of Medicine, Yale School of Medicine, 333 Cedar Street, LMP 2073, P.O. Box 208029, New Haven, Connecticut 06520. Tel.: 203-932-5711 ext. 2542.

Received 5 December 2006 ,Accepted 5 December 2006.

References 

  1. Brenner BM, Deen WM, Robertson CR. Determinants of glomerular filtration rate. Annu Rev Physiol. 1976;38:11–19
  2. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985;82:7580–7584
  3. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313:806–810
  4. Persson PB. Renin: origin, secretion and synthesis. J Physiol. 2003;552:667–671
  5. Humes HD. Acute renal failure: prevailing challenges and prospects for the future. Kidney Int Suppl. 1995;50:S26–S32
  6. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–1730
  7. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009–1016
  8. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524–537
  9. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699–706
  10. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295
  11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  12. DiBona GF. Neural control of renal function: role of renal alpha adrenoceptors. J Cardiovasc Pharmacol. 1985;7(suppl 8):S18–S23
  13. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev. 1979;59:919–957
  14. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–1918
  15. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239–3244
  16. DiBona GF. Neural control of renal function: cardiovascular implications. Hypertension. 1989;13:539–548
  17. Recordati GM, Moss NG, Waselkov L. Renal chemoreceptors in the rat. Circ Res. 1978;43:534–543
  18. Ziegler MG, Morrissey EC, Kennedy B, Elayan H. Sources of urinary catecholamines in renal denervated transplant recipients. J Hypertens. 1990;8:927–931
  19. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115:1275–1280
  20. Strausberg RL, Feingold EA, Klausner RD, Collins FS. The mammalian gene collection. Science. 1999;286:455–457
  21. Binda C, Mattevi A, Edmondson DE. Structure-function relationships in flavoenzyme-dependent amine oxidations: a comparison of polyamine oxidase and monoamine oxidase. J Biol Chem. 2002;277:23973–23976
  22. Jalkanen S, Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. Embo J. 2001;20:3893–3901
  23. Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol. 2002;9:22–26
  24. Ghosh SS, Gehr TWB, Sica DA, et al. Effect of renalase inhibition on blood pressure. J Am Soc Nephrol. 2006;17:208A
  25. Ghosh SS, Gehr TWB, Sica DA, et al. Renalase regulates blood pressure in salt sensitive Dahl rats. J Am Soc Nephrol. 2006;17:208A
  26. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002;40:41–46
  27. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354–1359
  28. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974–1979

 This article was supported by the Veterans’ Administration (Merit Review award) and by the NIH (DK48105B).Conflict of interest: none.

PII: S1933-1711(06)00011-8

doi: 10.1016/j.jash.2006.12.001

Journal of the American Society of Hypertension
Volume 1, Issue 2 , Pages 99-103 , March 2007

Article Tools

* Image Usage & Resolution